Pharmaceuticals, Biotechnology and Life Sciences
Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase…
PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company…
Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium PresentationHOUSTON, Jan. 08, 2026…
SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology…
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in…
— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years– BRISBANE,…
– Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks…
SAN DIEGO–(BUSINESS WIRE)–$ARCT #ClinicalTrial–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on…
NEW YORK–(BUSINESS WIRE)–GenNx360 Capital Partners (“GenNx360”), a New York City-based private equity firm investing in middle-market industrial and business services…
Investor Day on January 21, 2026, to present new product vision and AI solutions RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Simulations Plus,…